Navigation Links
Cempra to Present Data on Solithromycin's (CEM-101) Potential Against Urogenital Infections and Multidrug-Resistant Pathogens at ECCMID
Date:4/26/2013

CHAPEL HILL, N.C., April 26, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced that it will present data at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Berlin, demonstrating solithromycin's potential to treat urogenital infections and combat challenging pathogens such as enterococci and Legionella pneumophila. All of the presentations will occur on Sunday, April 28.

"Solithromycin, our fourth-generation macrolide, has the right spectrum of activity against a variety of serious gram positive pathogens as well as an emerging favorable safety profile," said Prabha Fernandes , Ph.D., chief executive officer of Cempra.  "The studies to be presented at ECCMID demonstrate the antibiotic's potential against bacterial urethritis as well as against serious pathogens such as enterococcus and Legionella for which therapeutic options are either few or decreasing due to increasing antibiotic resistance.  Solithromycin continues to differentiate itself against other treatments for community-acquired bacterial pneumonia, sexually-transmitted diseases and other serious infections."

Abstract O 274: 11:42-11:54 a.m. CEST: A phase II study to evaluate the efficacy and safety of single-dose oral solithromycin (CEM-101) for treatment of patients with uncomplicated urogenital gonorrhea

E. Hook, III, D. Oldach, B. Jamieson, K. Clark, P. Fernandes

  • Patients with suspected N. gonorrhoeae infections received a single oral 1,200 mg dose of solithromycin
  • Infections were eradicated from all 22 evaluable patients
    '/>"/>

SOURCE Cempra, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cempra, Inc. to Report First Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on May 10, 2012
2. Cempra, Inc. to Present at the Global Technology Community 9th Anti-Infectives Partnering and Deal-Making Conference
3. Cempra, Inc. to Report Second Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on August 8, 2012
4. Cempra, Inc. to Present at the NIAID Workshop Bridging the Gap - Overcoming Bottlenecks in the Development of Therapeutics for Infectious Diseases
5. Cempra, Inc. Reports Second Quarter 2012 Financial and Operating Results
6. Cempra, Inc., to Present at 2012 Stifel Nicolaus Healthcare Conference and NewsMakers in the Biotech Industry Conference
7. Cempra, Inc. to Report Third Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on November 8, 2012
8. Cempra, Inc. to Present at the Jefferies 2012 Global Healthcare Conference in London
9. Cempra, Inc. to Present at Oppenheimer 23rd Annual Healthcare Conference
10. Grant Awarded to Study Novel Therapies for Muco-Obstructive Diseases Includes Studies on Cempras Solithromycin (CEM-101) in a Cystic Fibrosis Anti-inflammatory Model
11. Cempra, Inc. to Report Fourth Quarter and Full Year 2012 Financial and Operating Results, and Host Conference Call and Webcast on February 28, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... 2014 The following is being released ... The Green Park Collaborative (GPC) will bring ... payers, medical device and pharmaceutical companies, as well ... 12, 2015 at its first ever workshop on ... treatments.  Participants will discuss study designs to evaluate ...
(Date:10/17/2014)...  UBM Medica US announces that Endocrinology Network ... clinicians who treat patients with type 2 diabetes ... of insulin .  Nearly all patients ... – daily injections of one or more insulin ... function of pancreatic beta cells. Insulin is a very ...
(Date:10/17/2014)... -- Ameritox SM , the nation,s leader in medication monitoring ... , M.D., as Chief Medical Officer. In this role, ... for healthcare providers, patients and managed care plans.   ... variety of healthcare companies that have provided him with ... health sides of Ameritox,s business. He most recently served ...
Breaking Medicine Technology:Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3Ameritox Appoints New Chief Medical Officer 2
... Visica 2(TM) Treatment System Selected as Exclusive Cryoablation ... ... The American College of,Surgeons Oncology Group (ACOSOG) which just ... Phase II Trial Exploring,the Success of Cryoablation Therapy in the ...
... results to be presented at 2008 ICAAC/IDSA ... Sequella, Inc., a,clinical-stage biopharmaceutical company focused ... epidemic potential, announces the,successful demonstration of synergistic ... resulting from in vitro combination,studies of Sequella ...
Cached Medicine Technology:NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation 2NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation 3Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207 2
(Date:10/20/2014)... 2014 Unveiled at the Sept. 18 board ... conservatively estimates member hospital ROI on membership dues at 12.5. ... Center provides $12.50 in value to member hospitals. The calculation ... Member Dues)/Member Dues. , “This is the first time ... we think the methodology is really sound,” said Bill ...
(Date:10/20/2014)... 2014 Punzoné , the first line ... has a lot to celebrate this month. October marks Italian ... achievements and contributions of Americans of Italian heritage and Italians ... today it shares its favorite Italian cocktails and encourages everyone ... - even if it is only in a glass. ...
(Date:10/20/2014)... USA (PRWEB) October 20, 2014 Do ... track interventions? Here comes a wonderful app Metassessor for ... app development company helped its client “Intervention Development ... efficiently. The app is designed for iOS 4.3 or ... touch. This app is optimized for iPhone 5. It ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 The ... iPage ( http://www.top10bestseohosting.com/go/iPage/ ) and GreenGeeks are the ... excellent platforms for those who want to buy ... same time. , The IT manager of Top10BestSEOHosting.com ... the most recommended suppliers for everyone. A lot ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 Dr. Babatunde ... Fund, welcomes news of a ceasefire agreement that is ... than 200 girls who were kidnapped from the north-eastern ... languished in captivity long enough, and it is high ... communities," stated Dr. Osotimehin. , "We owe it to ...
Breaking Medicine News(10 mins):Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2
...
...
...
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 35G x 5/8in (.50 x 16mm)...
Medicine Products: